OCTET-CY: A phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation

European Journal of Haematology

Volumn 96, Issue 1, 2016, Pages 27-35

  Holtick, Udo ^a   Chemnitz, Jens Markus ^a   Shimabukuro Vornhagen, Alexander ^a   Theurich, Sebastian ^a   Chakupurakal, Geothy ^a   Krause, Anke ^a   Fiedler, Anne ^a   Luznik, Leo ^b   Hellmich, Martin ^a   Wolf, Dominik ^c   Hallek, Michael ^a   von Bergwelt Baildon, Michael ^a   Scheid, Christof ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Post transplant cyclophosphamide

Indexed keywords

BUSULFAN; CD161 ANTIGEN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DUODENUM ULCER; ENGRAFTMENT; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MICROANGIOPATHY; MORTALITY; MUCOSA INFLAMMATION; MYELOMA; NATURAL KILLER CELL; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SEPSIS; SUBARACHNOID HEMORRHAGE; T LYMPHOCYTE; THROMBOCYTE; TREATMENT OUTCOME; ALLOGRAFT; BLOOD; CLINICAL TRIAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL;

ADULT; ALLOGRAFTS; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

EID: 84954467439     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12541     Document Type: Article

References (43)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373:1550-61.
2. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-35.
3. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-8.
4. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-14.
5. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;34:621-5.
6. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001;98:3868-70.
7. MacDonald KP, Shlomchik WD, Reddy P. Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant 2013;19(1 Suppl):S10-4.
8. Mayumi H, Good RA. The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice. Immunobiology 1989;178:287-304.
9. Mayumi H, Good RA. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med 1989;169:213-38.
10. Mayumi H, Himeno K, Tanaka K, Tokuda N, Fan JL, Nomoto K. Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease. Transplantation 1987;44:286-90.
11. Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002;8:131-8.
12. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50.
13. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010;16:482-9.
14. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285-91.
15. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, Solomon SR. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013;31:1310-6.
16. Solomon SR, Jacobson S, Sanacore M, Zhang X, Sizemore C, Brown S, Holland HK, Morris LE, Bashey A. Myeloablative Conditioning with PBSC grafts for T-replete haploidentical donor hematopoietic cell transplantation using post-transplant cyclophosphamide results in universal engraftment, low rates of Gvhd, NRM and excellent survival outcomes: an analysis of two consecutive phase II studies from a single center. Blood 2013;122:3351.
17. Perez-Corral AM, Gayoso J, Anguita J, et al. Early and favourable immune reconstitution after unmanipulated haploidentical stem cell transplantation with high dose post-transplant cyclophosphamide regardless intensity of conditioning regimen. Blood 2013;122:4620.
18. Castagna L, Crocchiolo R, Furst S, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014;20:724-9.
19. Raj K, Pagliuca A, Bradstock K, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014;20:890-5.
20. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010;47:65-77.
21. Kanakry CG, O'Donnell PV, Furlong T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014;32:3497-505.
22. Kanakry CG, Tsai HL, Bolanos-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 2014;124:3817-27.
23. StemCellTrialists. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
24. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:1487-96.
25. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014;4:CD010189.
26. Alousi AM, Saliba RM, Chen J, et al. A matched controlled analysis of post-transplant cyclophosphamide (CY) versus tacrolimus and mini-dose methotrexate in matched sibling and unrelated donor transplant recipients receiving reduced-intensity conditioning: post-transplant CY is associated with higher rates of acute Gvhd. Blood 2012;120:4200 abstract 4200.
27. Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, Bashey A. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2014;20:1828-34.
28. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2014;5:211ra157.
29. Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012;39:683-93.
30. Peccatori J, Oliveira G, Greco R, Marktel S, Lunghi F, Ciceri F, Bonini C. Tracking T cell dynamics in the first month after Haplo-HSCT with post-transplant cyclophosphamide reveals a predominant contribution of memory stem T cells to the early phase of immune reconstitution. Blood 2013;122:4615.
31. Ross D, Jones M, Komanduri K, Levy RB. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013;19:1430-8.
32. Luznik L, Fuchs EJ, Chen AR, Kaup M, Bright EC, Bolanos-Meade J, Hess AD, Jones RJ. Post-transplantation high-Dose cyclophosphamide (Cy) is effective single agent GvHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA-matched related and unrelated bone marrow transplantation (BMT). Biol Blood Marrow Transplant 2007;13 (2 Suppl. 1):4.
33. Greco R, Morelli M, Giglio F, et al. Post-transplant cyclophosphamide Haplo-HSCT revised: peripheral blood stem cell graft and sirolimus to enhance immune reconstitution and graft versus leukemia effect in patients with active leukemia. Blood 2013;122:2118.
34. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
35. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
36. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
37. Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115:3224-30.
38. Kroger N. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 2007;21:1851-8.
39. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418-25.
40. Ringden O, Shrestha S, da Silva GT, et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012;47:831-7.
41. Fergusson JR, Fleming VM, Klenerman P. CD161-expressing human T cells. Front Immunol 2011;2:36.
42. Jukes JP, Jones ND. Immunology in the clinic review series; focus on host responses: invariant natural killer T cell activation following transplantation. Clin Exp Immunol 2012;167:32-9.
43. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013;31:e59-63.